Karyopharm e Menarini Group recebem parecer positivo do CHMP para uso de NEXPOVIO® (selinexor) no tratamento de pacientes com mieloma múltiplo refratário ...Middle East

-- Decisão da Comissão Europeia aguardada dentro de aproximadamente 60 dias -- NEWTON, Massachusetts e FLORENÇA, Itália, 22 de maio de 2022 /PRNewswire/ -- A Karyopharm Therapeutics Inc. (Nasdaq: KPTI), uma empresa farmacêutica de fase comercial pioneira em novos tratamentos contra o...

Hence then, the article about karyopharm e menarini group recebem parecer positivo do chmp para uso de nexpovio selinexor no tratamento de pacientes com mieloma multiplo refratario was published today ( Sunday 22/05/2022 - 04:20 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Karyopharm e Menarini Group recebem parecer positivo do CHMP para uso de NEXPOVIO® (selinexor) no tratamento de pacientes com mieloma múltiplo refratário )

Also on site :

• As Colorado’s wildfire threat grows, Douglas County turns to biochar as ‘next level’ mitigation tool
• Numbrix 9 - February 1
• ‘Deeply insecure’: Why Bangladeshi minorities are scared ahead of elections